Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CODEX DNA, INC.

(DNAY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CODEX DNA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

08/10/2021 | 04:18pm EDT

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2021, Codex DNA, Inc. (the "Company") issued a press release (the "Press Release") announcing results for the quarter ended June 30, 2021. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

[[Image Removed: image.jpg]]

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.       Description
99.1                Press Release dated August 10, 2021

© Edgar Online, source Glimpses

Stocks mentioned in the article
ChangeLast1st jan.
CODEX DNA, INC. 2.16% 10.87 Delayed Quote.0.00%
GENTING BERHAD 1.16% 5.25 End-of-day quote.17.71%
All news about CODEX DNA, INC.
09/20CODEX DNA, INC.(NASDAQGS : DNAY) added to S&P TMI Index
CI
09/16CODEX DNA : Departure of Directors or Certain Officers; Election of Directors; Appointment..
PU
09/16CODEX DNA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/16Codex DNA, Inc. Announces Departure of Timothy E. Cloutier as Senior Vice President, Ef..
CI
09/01Codex Dna Releases Full-Length Synthetic Genome for Highly Infectious Sars-Cov-2 Delta ..
CI
08/11CODEX DNA : Management's discussion and analysis of financial condition and results of ope..
AQ
08/10CODEX DNA : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/10CODEX DNA, INC. : Results of Operations and Financial Condition, Financial Statements and ..
AQ
08/10CODEX DNA : Earnings Flash (DNAY) CODEX DNA Reports Q2 Revenue $2.9M, vs. Street Est of $2..
MT
08/10CODEX DNA : Reports Second Quarter 2021 Financial Results
AQ
More news
Analyst Recommendations on CODEX DNA, INC.
More recommendations
Financials (USD)
Sales 2021 12,5 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,98x
Yield 2021 -
Capitalization 318 M 318 M -
Capi. / Sales 2021 25,5x
Capi. / Sales 2022 15,4x
Nbr of Employees 108
Free-Float 47,3%
Chart CODEX DNA, INC.
Duration : Period :
Codex DNA, Inc. Technical Analysis Chart | DNAY | US1920031010 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 10,87 $
Average target price 26,50 $
Spread / Average Target 144%
EPS Revisions
Managers and Directors
Todd R. Nelson President, Chief Executive Officer & Director
Jennifer Isacoff McNealey Chief Financial Officer
Daniel G. Gibson Chief Technology Officer
Justin O. Emory Vice President-Information Technology
Franklin R. Witney Independent Director
Sector and Competitors